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Purpose: An ancillary phase II study was conducted to study interindividual
variability in cetuximab pharmacokinetics and its influence on progression-free
survival (PFS) in metastatic colorectal cancer patients cotreated with irinotecan and
5-fluorouracil. Experimental Design: Ninety-six patients received cetuximab as an
infusion loading dose of 400 mg/m2 followed by weekly infusions of 250 mg/m2.
Doses of irinotecan and 5-fluorouracil were adjusted individually. Cetuximab
concentrations were measured by ELISA. Compartmental pharmacokinetic
parameters were estimated by a population approach, and PFS was analyzed using a
Cox model. Results: Cetuximab pharmacokinetics was best described using a two-
compartment model with both first-order and saturable (zero-order) elimination.
Estimated pharmacokinetic parameters (% standard error) were as follows: central
volume of distribution V1 = 2.96 L (4%), peripheral volume of distribution V2 = 4.65
L (6%), elimination clearance CL = 0.497 L/d (4%), distribution clearance Q = 0.836
L/d (8%), and zero-order elimination rate k0 = 8.71 mg/d (10%). Body surface area
influenced V1, V2, and k0. Pretreatment serum albumin influenced CL. Risk of
disease progression decreased with cetuximab global clearance (cumulative
dose/cumulative area under the concentration versus time curve; P = 0.00016).
Median PFS of patients with a cetuximab residual concentration on day 14 below
median value was 3.3 months as compared with 7.8 months for the other patients (P
= 0.004). Conclusions: Cetuximab pharmacokinetics in colorectal cancer patients can
be described using a model combining linear and nonlinear elimination rates. PFS is
influenced by global clearance of cetuximab, a parameter that can be estimated
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